GlassScriptPhysician profile
Matthew R Call
NPI 1083904619
$17,498.20
in general payments reported to CMS, 2019-2025
35 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $2,088 · 2021: $2,095 · 2022: $2,658 · 2023: $2,516 · 2024: $3,070 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,987 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,987.07 |
| Education | $373.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,458.32 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,231.05 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,668.35 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,594.06 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,427.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,334.96 | 2019-2025 | |
| Lilly USA, LLC | $1,241.44 | 2019-2025 | Taltz, Olumiant |
| Astrazeneca Pharmaceuticals LP | $737.74 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $672.87 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $503.84 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $486.42 | 2019-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $363.37 | 2019-2025 | Actemra |
| Organon LLC | $352.25 | 2021-2025 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals, LTD. | $194.71 | 2021-2023 | Arcalyst |
| Celgene Corporation | $152.53 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $143.15 | 2023-2025 | Idacio, Tyenne |
| Merck Sharp & Dohme LLC | $142.64 | 2019-2021 | |
| Gilead Sciences, INC. | $132.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.98 | 2020-2025 | Cyltezo, Jascayd, Ofev |
| Sandoz INC. | $71.30 | 2023-2025 | Hyrimoz, Jubbonti |
| Collegium Pharmaceutical, INC. | $67.61 | 2024 | Belbuca |
| Kiniksa Pharmaceuticals International, Plc | $66.20 | 2024 | Arcalyst |
| Genzyme Corporation | $63.94 | 2020-2025 | |
| Genentech, INC. | $49.95 | 2021 | |
| Aurinia Pharma U.S., INC. | $44.23 | 2023-2024 | Lupkynis |
| Sobi, INC | $39.26 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.61 | 2022 | |
| Mylan Institutional INC. | $20.48 | 2023 | Hulio |
| Regeneron Healthcare Solutions, INC. | $19.28 | 2019 | |
| Biocon Biologics INC | $19.04 | 2025 | Hulio |
| Zyla Life Sciences, INC. | $15.94 | 2019 | |
| Boston Scientific Corporation | $15.53 | 2019 | |
| Antares Pharma, INC. | $14.60 | 2019 | |
| Radius Health, INC. | $13.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.89 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.